

**Vaccinia Virus, vSC56, Recombinant Expressing  $\beta$ -Galactosidase**

**Catalog No. NR-622**

This reagent is the property of the U.S. Government.

**For research use only. Not for human use.**

**Contributor:**

Bernard Moss, M.D., Ph.D., Chief, Laboratory of Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

**Manufacturer:**

Viral Antigens, Inc. (now Meridian Life Science®, Inc.)

**Product Description:**

Virus Classification: *Poxviridae, Orthopoxvirus*

Species: Vaccinia virus

Strain/Isolate: vSC56 (WR recombinant expressing  $\beta$ -galactosidase)

Original Source: Recombinant vaccinia virus, vSC56, was prepared by transfecting the transfer vector, pSC56, into cells infected with vaccinia virus strain WR. pSC56 contains a synthetic, vaccinia virus early/late promoter sequence and the *Escherichia coli lacZ* gene. Homologous recombination of pSC56 with vaccinia virus strain WR resulted in vSC56, a recombinant vaccinia virus expressing  $\beta$ -galactosidase.<sup>1</sup>

**Material Provided:**

Each vial contains approximately 50  $\mu$ L of cell lysate and supernatant from infected HeLa cells (BEI Resources NR-524) in Iscove's Modified Dulbecco's Medium supplemented with 2% fetal bovine serum (FBS).

**Packaging/Storage:**

NR-622 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -65°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

**Growth Conditions:**

Host: HeLa cells (BEI Resources NR-524)

Growth Medium: Iscove's Modified Dulbecco's Medium supplemented with 2% FBS

Infection: Cells should be approximately 90-95% confluent and virus added at a multiplicity of infection of 1

Incubation: 92 hours at 37°C and 5% CO<sub>2</sub>

Cytopathic Effect: Cell rounding and cell lysis

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vaccinia Virus, vSC56, Recombinant Expressing  $\beta$ -Galactosidase, NR-622."

**Biosafety Level: 2**

Appropriate safety procedures should always be used with this

material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

This publication recommends that all persons working in or entering laboratory or animal care areas where activities with vaccinia virus are being conducted should have documented evidence of satisfactory vaccination within the preceding ten years.

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Chakrabarti, S., J. R. Sisler and B. Moss. "Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression." Biotechniques 23 (1997): 1094-1097. PubMed: 9421642.

ATCC® is a trademark of the American Type Culture Collection.

